Loading news...
Bank of Hawaii reduced its stake in shares of Natera, Inc. (NASDAQ: NTRA) by 18.6% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,835 shares of the medical research company's stock after selling 4,072 shares during
We maintain our valuation discipline and our focus on companies with competitive advantages and skilled management teams that we believe are executing better than their peers. We initiated a position in Tractor Supply after recent share weakness created a compelling entry point, in our view. Tyler Technologies was sold because the software provider's revenue growth has decelerated, which reduced our conviction in its upside potential.
MENLO PARK, Calif., March 12, 2026 /PRNewswire/ -- MyOme, a leader in clinical whole-genome analysis, announced an advancement in rare disease diagnostics at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting.
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the commercial launch of Zenith genomics, its next-generation whole genome sequencing assay designed to significantly improve the detection of rare diseases. Natera is presenting on Zenith's unique platform and performance at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting, taking place this week in Baltimore, Ma.
Natera, Inc. (NTRA) Presents at Leerink Global Healthcare Conference 2026 Transcript
Focus Partners Advisor Solutions LLC grew its stake in Natera, Inc. (NASDAQ: NTRA) by 72.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,540 shares of the medical research company's stock after buying an additional 4,421 shares during the period. Focus
Natera, Inc. (NTRA) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Natera, Inc. (NTRA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced it will present new data in genitourinary malignancies at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place February 26-28, 2026. Across four oral presentations in muscle-invasive bladder cancer (MIBC), these data reinforce Signatera's role in identifying patients who benefit from adjuvant immunotherapy, supporting.
Natera, Inc. (NASDAQ: NTRA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eighteen analysts that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, thirteen have given a buy recommendation and one has given
Natera, Inc. (NTRA) Q4 2025 Earnings Call Transcript
Natera (NTRA) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of a loss of $0.46 per share. This compares to a loss of $0.41 per share a year ago.
The headline numbers for Natera (NTRA) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Investor attention turned more intensely to the scale, timing, and funding of AI-related capital commitments, prompting renewed debate about whether expectations were running ahead of eventual monetization. The Russell 1000 Value Index returned 3.81% during the quarter, outperforming the Russell 1000 Growth Index's return of 1.12% by nearly 270 basis points. Under its 'pivot to growth' strategy, Teva has expanded its biosimilars portfolio and strengthened its generics business, returning that segment to positive growth.
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the fourth quarter and full year ended December 31, 2025. Recent Financial Highlights Generated total revenues of $665.5 million in the fourth quarter of 2025, compared to $476.1 million in the fourth quarter of 2024, an increase of 39.8%. Product revenues grew 39.8% over the same period. Generated a gross margin1 of 66.9% in the fourth quar.
Fox Run Management L.L.C. boosted its stake in Natera, Inc. (NASDAQ: NTRA) by 42.5% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,713 shares of the medical research company's stock after acquiring an additional 3,491 shares during the quarter. Fox
For the quarter, Alger SICAV - Alger Dynamic Opportunities Fund portfolio's average long exposure was 80.88% and the average short exposure was -32.28%. Long positions MongoDB, Inc., Natera, Inc., and Alphabet Inc. were among the top contributors to performance. Long positions Meta Platforms Inc., Nebius Group, and Roblox Corp. were among the top detractors from performance.
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the SINERGY trial, a Phase 2 study in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Data was recently presented in an oral plenary at the 2026 MHNCS. Approximately 73K patients are diagnosed with head and neck cancer in the U.S. annually.1 The current standard of care for R/M HNSCC patients, based on the registrational KE.
Beyond analysts' top-and-bottom-line estimates for Natera (NTRA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2025.
One investment is a fast-growing genetic testing company that's now generating cash flow and has a scalable business model. The leading semiconductor foundry's sales are booming on AI-led demand, but expanding cash-flow margins will be a challenge.